Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 17/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639632 | 0.88 | CCR1 (0.67) | CCR1CYP2C19KCNH2 | |
| SCHEMBL12726335 | 0.86 | CCR1 (0.51) | CCR1MAPTMEN1HTTKMT2A | |
| SCHEMBL12726355 | 0.85 | CCR1 (0.55) | CCR1MAPTMEN1HTTKMT2A | |
| SCHEMBL12726187 | 0.84 | CCR1 (0.55) | CCR1MAPTTP53CYP2C19KCNH2 | |
| SCHEMBL10063606 | 0.83 | CCR1 (0.57) | CCR1TP53CYP2C19KCNH2 | |
| SCHEMBL13229297 | 0.83 | CCR1 (0.55) | CCR1MAPTCYP2C19KCNH2 | |
| SCHEMBL14620906 | 0.82 | CCR1 (0.70) | CCR1CYP2C19KCNH2 | |
| SCHEMBL12726360 | 0.82 | CCR1 (0.58) | CCR1CYP2C19KCNH2 | |
| SCHEMBL12726239 | 0.81 | CCR1 (0.59) | CCR1TP53CYP2C19KCNH2 | |
| SCHEMBL12726229 | 0.81 | CCR1 (0.59) | CCR1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9296740-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-8383630-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885MAPT 4546/4885MEN1 4604/4885 |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885MAPT 4546/4885MEN1 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.